Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 15.03.2021 2 AJR Am J Roentgenol 1 Ann Surg 3 Ann Surg Oncol 3 BMC Cancer 4 Breast Cancer 1 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 9 Breast Cancer Res Treat 3 Breast J 1 Cancer 1 Cancer Cell 1 Cancer Res 5 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 2 Eur J Surg Oncol 1 Eur Radiol 3 Int J Cancer 5 J Clin Oncol 1 J Surg Oncol 3 Lancet Oncol 1 NPJ Breast Cancer 2 Oncogene 1 Oncology 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. MICHAELS AY, Ginter PS, Dodelzon K, Naunheim MR, et al
   High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management.
   AJR Am J Roentgenol. 2021 Jan 13:1-11. doi: 10.2214/AJR.20.23040.
   PubMed         Abstract available
   
   
2. ECKSTEIN DA, Price ER, Hayward JH, Joe BN, et al
   Frequency and Outcomes of New Suspicious Lesions on Breast MRI in the Setting of Neoadjuvant Therapy.
   AJR Am J Roentgenol. 2021 Jan 13:1-7. doi: 10.2214/AJR.20.22979.
   PubMed         Abstract available
   
   

   
   Ann Surg

3. DECOSTER RC, Lynch EB, Bonaroti AR, Webster JM, et al
   Breast Implant-associated Anaplastic Large Cell Lymphoma: An Evidence-based Systematic Review.
   Ann Surg. 2021;273:449-458.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. CASTELO M, Scheer AS
   ASO Author Reflections: Completion Axillary Dissection Can Be Avoided but Inconsistent Trial Design Complicates Choosing Between Alternative Strategies.
   Ann Surg Oncol. 2020;27:2677-2678.
   PubMed        
   
   
5. TANG A, Shim V
   ASO Author Reflections: Balancing Patient Choice and Risks/Benefits of Radiation Treatment in Early Breast Cancer: How Does One Choose?
   Ann Surg Oncol. 2021 Mar 6. pii: 10.1245/s10434-021-09677.
   PubMed        
   
   
6. DAVIES CF, Macefield R, Avery K, Blazeby JM, et al
   Patient-Reported Outcome Measures for Post-mastectomy Breast Reconstruction: A Systematic Review of Development and Measurement Properties.
   Ann Surg Oncol. 2021;28:386-404.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
   Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
   BMC Cancer. 2021;21:239.
   PubMed         Abstract available
   
   
8. ABSIL L, Journe F, Larsimont D, Body JJ, et al
   Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
   BMC Cancer. 2020;20:640.
   PubMed         Abstract available
   
   
9. JI L, Cheng L, Zhu X, Gao Y, et al
   Risk and prognostic factors of breast cancer with liver metastases.
   BMC Cancer. 2021;21:238.
   PubMed         Abstract available
   
   

   
   Breast Cancer

10. TAKAHASHI M, Inoue K, Mukai H, Yamanaka T, et al
    Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Breast Cancer. 2021 Mar 7. pii: 10.1007/s12282-021-01232.
    PubMed         Abstract available
    
    
11. TAN PY, Teng KT
    Role of dietary fat on obesity-related postmenopausal breast cancer: insights from mouse models and methodological considerations.
    Breast Cancer. 2021 Mar 9. pii: 10.1007/s12282-021-01233.
    PubMed         Abstract available
    
    
12. WANG LF, Eaglehouse YL, Poppenberg JT, Brufsky JW, et al
    Effects of a personal trainer-led exercise intervention on physical activity, physical function, and quality of life of breast cancer survivors.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-020-01211.
    PubMed         Abstract available
    
    
13. VINH-HUNG V, Everaert H, Gorobets O, Van Parijs H, et al
    Breast cancer preoperative (18)FDG-PET, overall survival prognostic separation compared with the lymph node ratio.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-021-01234.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

14. ELIAN FA, Are U, Ghosh S, Nuin P, et al
    FOXQ1 is Differentially Expressed Across Breast Cancer Subtypes with Low Expression Associated with Poor Overall Survival.
    Breast Cancer (Dove Med Press). 2021;13:171-188.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

15. DARRIGUES L, Pierga JY, Bernard-Tessier A, Bieche I, et al
    Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Breast Cancer Res. 2021;23:31.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

16. CHAWLA S, Hill A, Fearfield L, Johnston S, et al
    Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06169.
    PubMed         Abstract available
    
    
17. FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
    Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
    Breast Cancer Res Treat. 2021 Mar 12. pii: 10.1007/s10549-021-06168.
    PubMed         Abstract available
    
    
18. LI XM, Chen HL
    RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients.
    Breast Cancer Res Treat. 2021 Mar 11. pii: 10.1007/s10549-021-06146.
    PubMed        
    
    
19. FEI F, Siegal GP, Wei S
    Characterization of estrogen receptor-low-positive breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06148.
    PubMed         Abstract available
    
    
20. MOOSSDORFF M, Vane MLG, van Nijnatten TJA, van Maaren MC, et al
    Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-020-06040.
    PubMed         Abstract available
    
    
21. DANKWA-MULLAN I, George J, Roebuck MC, Tkacz J, et al
    Variations in breast cancer surgical treatment and timing: determinants and disparities.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06155.
    PubMed         Abstract available
    
    
22. PRADA D, Baccarelli AA, Terry MB, Valdez L, et al
    Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06167.
    PubMed         Abstract available
    
    
23. NGUYEN T, Irwin ML, Dewan AT, Cartmel B, et al
    Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention.
    Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06151.
    PubMed         Abstract available
    
    
24. LUO J, Kroenke CH, Hendryx M, Shadyab AH, et al
    Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.
    Breast Cancer Res Treat. 2021 Mar 7. pii: 10.1007/s10549-021-06158.
    PubMed         Abstract available
    
    

    
    Breast J

25. BARBA M, Krasniqi E, Pizzuti L, Mazzotta M, et al
    COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
    Breast J. 2021 Mar 6. doi: 10.1111/tbj.14204.
    PubMed         Abstract available
    
    
26. LOHANI KR, Kumar C, Kataria K, Srivastava A, et al
    Role of tranexamic acid in axillary lymph node dissection in breast cancer patients: Does it help in reducing lymphedema?
    Breast J. 2021 Mar 11. doi: 10.1111/tbj.14222.
    PubMed        
    
    
27. ROBERSON PNE, Cortez G, Lenger K, Bell C, et al
    Quality of life fluctuations before and after breast surgery for estrogen-positive breast cancer patients living in South-Central Appalachia: A prospective pilot study.
    Breast J. 2021 Mar 11. doi: 10.1111/tbj.14183.
    PubMed        
    
    

    
    Cancer

28. FAN R, Chen Y, Nechuta S, Cai H, et al
    Prediction models for breast cancer prognosis among Asian women.
    Cancer. 2021 Mar 11. doi: 10.1002/cncr.33425.
    PubMed         Abstract available
    
    

    
    Cancer Cell

29. CUNNINGHAM NC, Turner NC
    Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer.
    Cancer Cell. 2021;39:307-309.
    PubMed         Abstract available
    
    

    
    Cancer Res

30. CAI Y, Xu G, Wu F, Michelini F, et al
    Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kalpha inhibitors.
    Cancer Res. 2021 Mar 8. pii: 0008-5472.CAN-20-3232.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

31. TAKASHIMA T, Hara F, Iwamoto T, Uemura Y, et al
    A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
    Clin Breast Cancer. 2021 Feb 1. pii: S1526-8209(21)00040.
    PubMed         Abstract available
    
    
32. CAZZANIGA ME, Giordano M, Bandera M, Cassani C, et al
    Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project.
    Clin Breast Cancer. 2021 Feb 1. pii: S1526-8209(21)00022.
    PubMed         Abstract available
    
    
33. VIDAL GA, Carter GC, Gilligan AM, Saverno K, et al
    Development of a Prognostic Factor Index Among Women With HR(+)/HER2(-) Metastatic Breast Cancer in a Community Oncology Setting.
    Clin Breast Cancer. 2021 Jan 1. pii: S1526-8209(20)30340.
    PubMed         Abstract available
    
    
34. HUANG X, Lin S, Rao X, Zeng D, et al
    First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Clin Breast Cancer. 2021 Feb 4. pii: S1526-8209(21)00041.
    PubMed         Abstract available
    
    
35. JACKISCH C, Barcenas CH, Bartsch R, Palma JD, et al
    Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
    Clin Breast Cancer. 2021 Feb 6. pii: S1526-8209(21)00043.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

36. BRAVACCINI S, Ravaioli S, Tumedei MM, Rocca A, et al
    Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
    Clin Cancer Res. 2020;26:3892-3893.
    PubMed        
    
    

    
    Eur J Cancer

37. HOUSSAMI N, Zackrisson S, Blazek K, Hunter K, et al
    Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening.
    Eur J Cancer. 2021;148:14-23.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

38. SASADA S, Kimura Y, Masumoto N, Emi A, et al
    Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors.
    Eur J Surg Oncol. 2021 Mar 3. pii: S0748-7983(21)00117.
    PubMed         Abstract available
    
    
39. CORSO G, Magnoni F, Montagna G, Maisonneuve P, et al
    Long-term outcome and axillary recurrence in elderly women (>/=70 years) with breast cancer: 10-years follow-up from a matched cohort study.
    Eur J Surg Oncol. 2021 Mar 3. pii: S0748-7983(21)00118.
    PubMed         Abstract available
    
    

    
    Eur Radiol

40. EUN NL, Kang D, Son EJ, Youk JH, et al
    Texture analysis using machine learning-based 3-T magnetic resonance imaging for predicting recurrence in breast cancer patients treated with neoadjuvant chemotherapy.
    Eur Radiol. 2021 Mar 10. pii: 10.1007/s00330-021-07816.
    PubMed         Abstract available
    
    

    
    Int J Cancer

41. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed         Abstract available
    
    
42. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed         Abstract available
    
    
43. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

44. WRIGHT JL, Bellon JR
    Is the Time Right for Five-Fraction Partial Breast Irradiation?
    J Clin Oncol. 2020;38:4135-4137.
    PubMed        
    
    
45. MCDONNELL DP, Wardell SE, Chang CY, Norris JD, et al
    Next-Generation Endocrine Therapies for Breast Cancer.
    J Clin Oncol. 2021 Mar 11:JCO2003565. doi: 10.1200/JCO.20.03565.
    PubMed        
    
    
46. AZIM HA JR, Ameye L, Paesmans M, Lambertini M, et al
    Reply to S. A. Narod et al.
    J Clin Oncol. 2020;38:4352-4354.
    PubMed        
    
    
47. WANG SL, Fang H, Hu C, Song YW, et al
    Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
    J Clin Oncol. 2020;38:3604-3614.
    PubMed         Abstract available
    
    
48. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    PubMed        
    
    

    
    J Surg Oncol

49. NAKAMURA R, Hayama S, Sonoda I, Miyaki T, et al
    Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy.
    J Surg Oncol. 2021 Mar 8. doi: 10.1002/jso.26438.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

50. ANDERSON BO, Ilbawi AM, Fidarova E, Weiderpass E, et al
    The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases.
    Lancet Oncol. 2021 Mar 5. pii: S1470-2045(21)00071.
    PubMed        
    
    
51. AMIR E, Cescon DW
    Pembrolizumab monotherapy in metastatic triple-negative breast cancer.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(21)00019.
    PubMed        
    
    
52. WINER EP, Lipatov O, Im SA, Goncalves A, et al
    Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(20)30754.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

53. ARTZY-RANDRUP Y, Epstein T, Brown JS, Costa RLB, et al
    Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy.
    NPJ Breast Cancer. 2021;7:26.
    PubMed         Abstract available
    
    

    
    Oncogene

54. KIM H, Son S, Ko Y, Shin I, et al
    CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01731.
    PubMed         Abstract available
    
    
55. BERDIEL-ACER M, Maia A, Hristova Z, Borgoni S, et al
    Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01719.
    PubMed         Abstract available
    
    

    
    Oncology

56. MADEKIVI V, Karlsson A, Bostrom P, Salminen E, et al
    Are Breast Cancer Nomograms Still Valid to Predict the Need for Axillary Dissection?
    Oncology. 2021 Mar 10:1-5. doi: 10.1159/000514616.
    PubMed         Abstract available
    
    

    
    PLoS One

57. OLSEN KS, Holden M, Thalabard JC, Rasmussen Busund LT, et al
    Global blood gene expression profiles following a breast cancer diagnosis-Clinical follow-up in the NOWAC post-genome cohort.
    PLoS One. 2021;16:e0246650.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: